Tradewind BioScience

Tradewind BioScience is a biotechnology startup dedicated to developing innovative therapeutics for aggressive cancers. The company's lead program involves a high-affinity, multifaceted attack antibody that inhibits a validated target protein, demonstrating efficacy in in vivo studies. Tradewind's focus on biomarker identification ensures that their therapeutics will significantly benefit patients with the most meaningful impact, with an initial focus on ovarian cancer. Established in 2017 and based in the United States, Tradewind has received a $120.00K Seed Round investment from Y Combinator in January 2018. With backing from Y Combinator and the National Cancer Institute (NCI), Tradewind seeks to revolutionize cancer treatment with its groundbreaking approach.